How long does semaglutide stay within specification at minus 20 °C once reconstituted?

Conditions: semaglutide · minus 20 °C.

I have done this once and I suspect I got away with it rather than got it right.

For context: I keep records of every batch, every lot number and every result, so an answer that requires me to track something is fine.

What does a defensible version of this look like in practice?

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

In practice, freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

Asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Cold, dry, dark, still. Those four words cover most of the mitigation.

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

At dilute concentrations, suspect adsorption before you suspect chemistry.

Aggregation is a physical process and is the one most often caused by handling rather than by time.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Deamidation kinetics for asparagine in peptides are well characterised and strongly sequence-dependent: the residue following the asparagine dominates the rate, with glycine and serine at the n+1 position accelerating it by an order of magnitude relative to bulkier residues. That is why two peptides in the same buffer at the same temperature can have quite different shelf lives.

Swirl, never shake. Aggregation is a handling problem more than a time problem.